These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 22965904)
1. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. Jung HJ; Chen Z; McCarty N Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904 [TBL] [Abstract][Full Text] [Related]
2. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552 [TBL] [Abstract][Full Text] [Related]
3. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045 [TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib. Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857 [TBL] [Abstract][Full Text] [Related]
5. [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro]. Sun QX; Meng FY; Fu YB; Li L; Tian S Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1022-5. PubMed ID: 17666343 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108 [TBL] [Abstract][Full Text] [Related]
7. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303 [TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Leonard JP; Furman RR; Coleman M Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600 [TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969 [TBL] [Abstract][Full Text] [Related]
10. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA MAbs; 2009; 1(1):31-40. PubMed ID: 20046572 [TBL] [Abstract][Full Text] [Related]
11. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514 [TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280 [TBL] [Abstract][Full Text] [Related]
13. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835 [TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792 [TBL] [Abstract][Full Text] [Related]
15. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334 [TBL] [Abstract][Full Text] [Related]
16. The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1. Li XY; Li Y; Zhang L; Liu X; Feng L; Wang X Oncol Rep; 2017 Nov; 38(5):3114-3120. PubMed ID: 28901456 [TBL] [Abstract][Full Text] [Related]
17. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080 [TBL] [Abstract][Full Text] [Related]
18. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726 [TBL] [Abstract][Full Text] [Related]
19. [Effect of arsenic trioxide on induction of apoptosis in MCL cell line and its possible mechanisms]. Fei AM; Mao CM; Liu JJ; Zhu J; Mi JQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):909-13. PubMed ID: 20723298 [TBL] [Abstract][Full Text] [Related]
20. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]